ACET — Adicet Bio Share Price
Last Trade - 00:00- $214.11m
- -$9.31m
- $13.92m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 17.9 | 2.76 | 0.75 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Adicet Bio Inc., formerly resTORbio, Inc., is a biotechnology company. The Company is focused on developing allogeneic gamma delta T cell therapies for cancer and other diseases. It is developing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enable selective tumor targeting, facilitate innate and adaptive anti-tumor immune response and improve persistence for durable activity in patients. Its pipeline includes ADI-001, ADI-002 and ADI-00x. ADI-001 is a gamma delta chimeric antigen receptor (CAR)-modified T cell therapy targeting CD20. ADI-002 is a gamma delta T cell containing a CAR that is specific for glypican 3 protein (GPC3). The Company is focused on developing ADI-00x for solid tumors and solid tumor and hematological indications.
Directors
- Chen Schor PRE (47)
- Nick Harvey
- Carrie Krehlik
- Francesco Galimi
- Don Healey (55)
- Steve Dubin (61)
- Carl Gordon (56)
- Aya Jakobovits
- Bastiano Sanna (46)
- Andrew Sinclair (49)
- Jeffrey Chodakewitz (65)
- Last Annual
- December 31st, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- July 5th, 2016
- Public Since
- January 26th, 2018
- No. of Shareholders
- 45
- No. of Employees
- 81
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 31,813,542
- Address
- 200 CLARENDON STREET, FLOOR 6, BOSTON, 02116
- Web
- https://www.adicetbio.com/
- Phone
- +1 6174822333
- Auditors
- PricewaterhouseCoopers LLP
Latest News for ACET
Upcoming events for ACET
Q3 2021 Adicet Bio Inc Earnings Release
Similar to ACET
AC IMMUNE SA ORD
NASDAQ Global Market
ADAMAS PHARMACEUTICALS ORD
NASDAQ Global Market
AEROVATE THERAPEUTICS ORD
NASDAQ Global Market
AMICUS THERAPEUTICS ORD
NASDAQ Global Market
ARCTURUS THERAPEUTICS HOLDINGS ORD
NASDAQ Global Market
FAQ
As of Today at 19:56 UTC, shares in Adicet Bio are trading at $6.73. This share price information is delayed by 15 minutes.
Shares in Adicet Bio last closed at $6.73 and the price had moved by -57.27% over the past 365 days. In terms of relative price strength the Adicet Bio share price has underperformed the S&P500 Index by -67.58% over the past year.
The overall consensus recommendation for Adicet Bio is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Adicet Bio does not currently pay a dividend.
Adicet Bio does not currently pay a dividend.
Adicet Bio does not currently pay a dividend.
To buy shares in Adicet Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $6.73, shares in Adicet Bio had a market capitalisation of $214.11m.
Here are the trading details for Adicet Bio:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ACET
Based on an overall assessment of its quality, value and momentum Adicet Bio is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Adicet Bio is $28.29. That is 320.36% above the last closing price of $6.73.
Analysts covering Adicet Bio currently have a consensus Earnings Per Share (EPS) forecast of -$2.49 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Adicet Bio. Over the past six months, its share price has underperformed the S&P500 Index by -62.76%.
As of the last closing price of $6.73, shares in Adicet Bio were trading -45.98% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Adicet Bio.
Adicet Bio's management team is headed by:
- Chen Schor - PRE
- Nick Harvey -
- Carrie Krehlik -
- Francesco Galimi -
- Don Healey -
- Steve Dubin -
- Carl Gordon -
- Aya Jakobovits -
- Bastiano Sanna -
- Andrew Sinclair -
- Jeffrey Chodakewitz -
We do not have data on Adicet Bio's shareholders